Global Andersen-Tawil Syndrome Market – Insights on Current Scope 2031

Posted by Prasad on April 21st, 2021

Andersen-Tawil syndrome is considered a rare form of periodic paralysis and is a type of long QT syndrome. The Andersen- tawil syndrome leads to changes in heart rhythm (arrhythmia). Episodes of muscle weakness and developmental abnormalities is also observed in patients with Andersen-tawil syndrome. Head, face, and limbs are primarily affected in the physical abnormalities associated with this condition.  Andersen-Tawil syndrome is caused by mutations in the KCNJ2 gene in some cases. While in other cases, the associated gene is unknown. The KCNJ2 gene mutation can be inherited in an autosomal dominant manner and occur randomly for unknown reasons (sporadically).

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=5273

Andersen-Tawil Syndrome Market: Segmentation

Tentatively, the global Andersen-Tawil Syndrome Market has been segmented on the basis of disease type, drug-class and distribution channel.

Based on disease type, the global Andersen-Tawil Syndrome Market is segmented as:

  • Type 1
  • Type 2

Based on Drug-class, the global Andersen-Tawil Syndrome Market is segmented as:

  • Carbonic anhydrate Inhibitors
  • Acetazolamide
  • Dichlorpenamide
  • Antiarrhythmic drugs
    • Amiodarone
    • Flecainide
  • Beta-Blockers
    • Atenolol

Based on distribution channel, the global Andersen-Tawil Syndrome Market is segmented as:

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

Andersen-Tawil Syndrome Market: Drivers and Restraints

Increase in the prevalence of Andersen-tawill syndrome is expected to drive the growth of the market. The increasing focus of the government to prioritize drugs for the treatment of rare diseases may also propel the growth of the Andersen-tawil syndrome market during the forecast period. The increasing participation of organizations to support the treatment and to create awareness is also expected to drive the growth of the market. The rising R&D investments by the key players in the Andersen-Tawil Syndrome Market is also expected to boost the growth of the market.

However, the lack of large clinical studies may restrict the growth of the Andersen-tawil syndrome market. The shortage of healthcare expects in Middle East & Africa and Latin America may restrain the growth of the Andersen-Tawil Syndrome market in this region.

Andersen-Tawil Syndrome Market: Key players

Some of the players identified in the Andersen-Tawil Syndrome Market include:

  • Teva Pharmaceuticals Ltd.
  • Zydus Pharmaceuticals, Inc.
  • Sun Pharmaceuticals Industries Ltd.
  • Advanz Pharmaceticals
  • Novartis AG
  • Mylan N.V.

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Like it? Share it!


Prasad

About the Author

Prasad
Joined: January 19th, 2021
Articles Posted: 51

More by this author